Lilly’s profit, sales forecast falls
Eli Lilly and Co. predicted its 2015 sales will come in roughly $1 billion less than analysts have expected, due to the strength of the U.S. dollar against foreign currencies.
Eli Lilly and Co.
Articles
Novartis expects price war with Lilly over psoriasis drugs
Novartis AG is racing to establish itself in the market for new treatments for psoriasis ahead of competing drugs by Amgen Inc. and Eli Lilly and Co. in the United States.
CEO Roundup: We’re not your father’s health care company anymore
The CEOs of Anthem, Lilly, Zimmer and Hill-Rom tried to woo investors at the J.P. Morgan Healthcare conference by stressing how they’re broadening business beyond plain-old insurance, pharmaceuticals, implants and hospital beds.
Lilly sees insurers pushing harder for discounts
Health-coverage managers are becoming more aggressive in demanding discounts and exclusive deals from drugmakers to drive down the cost of medicine, Eli Lilly and Co.’s diabetes business chief says.
UPDATE: Lilly says it couldn’t have made tainted Cialis
A batch of Cialis pills, purportedly made at a plant in Australia, was banned by the FDA from entering the U.S. after the pills were found to contain the active ingredient for rival drug Viagra. Cialis manufacturer Eli Lilly said it doesn’t make any drugs in Australia.
Obamacare’s effects on Lilly: Modest pain, no gain
Since Obamcare was expected to boost insurance coverage nationally by 32 million people, drugmakers like Eli Lilly and Co. stood to benefit. But it’s not working out that way. At least not for Lilly.
UPDATE: Lilly forecasts earnings below analyst expectations
The Indianapolis-based drugmaker said its long-term strategy is on track, but predicted sales this year would be $20.3 billion to $20.8 billion, a shade below what Wall Street was expecting.
Lilly to sell heartworm line for Novartis deal approval
Eli Lilly and Co. wants to combine Novartis with its own animal health business, Elanco, to create the second-largest animal health company in the U.S.
Lilly reaches insulin development deal with Adocia
Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
Lilly bumps up dividend for first time since 2009
Shares of Eli Lilly and Co. were on the rise Tuesday morning, a day after the drugmaker announced its first dividend increase in more than five years.
Lilly’s Cyramza gets new marketing approval
Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.
Alzheimer’s tests present dilemma of knowing the future
While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
Covance shareholder sues over $6.1B LabCorp deal
A Covance Inc. investor contends in a lawsuit that the drug-testing company’s board erred in relying on what the shareholder called Goldman Sachs Group Inc.’s conflict-tainted advice. Covance has major laboratory operations in Indianapolis.
Lilly rheumatoid arthritis drug meets goals in final-stage trial
If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.
Feds drop case against former Lilly scientists accused of stealing secrets
Federal prosecutors dropped all charges against two scientists accused of stealing trade secrets worth $55 million from Eli Lilly and Co. after new information emerged last month, according to a court motion made Friday.
Lilly competitor claims early success with Alzheimer’s drug
Biogen Idec Inc. shares rose Tuesday after the company said its Alzheimer’s drug showed promising early results and will be quickly moved into a final-stage trial.
Lilly in $440M osteoporosis patch deal with Zosano
Eli Lilly and Co. said Tuesday it will team up with Zosano Pharma Corp. on an experimental osteoporosis patch in a deal that could be worth more than $440 million.
Fifth person pleads guilty in Lilly warehouse heist
Prosecutors say the theft from an Eli Lilly and Co. warehouse in Connecticut involved up to $100 million in prescription drugs.
New type of cholesterol drug shows promise in study
The results have immediate implications for 1 million Americans who suffer mild heart attacks or chest pain each year. They may also make it easier for other experimental medicines from companies such as Eli Lilly to reach patients.
Top 4 questions for Hoosier health care after GOP takes control of Congress
On Obamacare, the new Republican-controlled Congress should “leave the façade of the building and then demolish the inside of it,” according to one GOP leader. If Republicans take that approach, here are four things that could change in the next two years.